Nowadays, the number of patients who suffer from bone cancer is rapidly increasing. Long-term treatment is needed, which mostly includes combination of surgical procedures and drug chemotherapy. This often adversely affects the health of patients, causing neurological disorders and heart diseases. Furthermore, tumour resection leaves a large void at the affected bone site that preferably must be filled with an appropriate biomaterial, such as calcium phosphate bone cements (CPCs), due to their ability to regenerate the missing tissues and, also, to serve as local drug delivery systems. Thus, the aim of the current study was to evaluate the effect of the drug addition and the variation of different solid and liquid phase compositions on the physico-chemical properties of prepared CPCs, as well as on the drug release kinetics. CPCs were prepared by using α-tricalcium phosphate (α-TCP) as a solid phase (synthesized at different temperatures) and 0.5 M and 1 M sodium salt solutions as the liquid phase. Doxorubicin (DOX) was used as a model anticancer drug and its content in CPCs was kept at 1.5wt% from the solid phase. Obtained cements were characterized using XRD, Archimedes method, helium pycnometry, BET and SEM. The release kinetics of the DOX were determined by UV-VIS at λ=480nm. Obtained results revealed that the release of doxorubicin from the CPCs can be controlled not only by varying the solid phase synthesis temperature, but also by changing the molarity of the liquid phase. It was also found that the addition of DOX affects the setting time and porosity of CPCs, but does not influence the CPC density. Finally, it was established that DOX-loaded CPCs are able to release the active substance for more than 60 days. According to the results, DOX loaded CPCs have a great potential to be used as a porous injectable biomaterial for bone tissue regeneration and drug delivery, however future studies are necessary to demonstrate their efficiency for osteosarcoma treatment. The authors acknowledge financial support from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No. 857287 (BBCE – Baltic Biomaterials Centre of Excellence) and the Ministry of Economics Republic of Latvia project "State research project in the field of biomedicine, medical technologies and pharmacy", project No. VPP-EM-BIOMEDICĪNA-2022/1-0001.